MLAB on Nasdaq
MESA LABORATORIES INC /CO/
In its 2026 annual report the company says: “We are a global leader in the design and manufacture of life sciences tools and critical quality control solutions for regulated applications in the pharmaceutical, healthcare and medical device industries. We offer products and services to help our customers ensure product integrity, increase patient and worker safety, and improve the quality of life throughout the world.”6 It is headquartered in Lakewood, United States.2 Its shares trade on Nasdaq under the symbol MLAB.2
Price unavailable
Last updated Oct 21, 2026.
Overview
Compare with HURCO COMPANIES INC, SYPRIS SOLUTIONS INC or Cognex Corporation, or pick any stock.
- TickerMLAB on Nasdaq2
- IndustryIndustrial Instruments For Measurement, Display, and Control2
- HeadquartersLakewood, United States2
- Incorporated inCO4
- Business address12100 W 6Th Ave, Lakewood, Co 802284
- Filer categoryAccelerated filer4
- Legal formBusiness Corporation2
- LEI549300ZCG738WLX8ZW792
- StatusActive2
- LEI statusIssued and current2
- Registered addressc/o John Sakys, 12100 West 6th Avenue, 80228 Lakewood, United States2
- Registered withBusiness Division of the Secretary of State’s office, 198714696182
See how the biggest companies compare on our leaderboards
We are a global leader in the design and manufacture of life sciences tools and critical quality control solutions for regulated applications in the pharmaceutical, healthcare and medical device industries. We offer products and services to help our customers ensure product integrity, increase patient and worker safety, and improve the quality of life throughout the world. We have manufacturing operations in the United States and Europe, and our products are marketed by our sales personnel in North America, Europe and the Asia Pacific region ("APAC"), and by independent distributors throughout the world.6 From its latest annual report
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2026
63.5%Gross margin3
7.4%Operating margin3
2.7%Net margin3
3.4%Revenue growth, 20263
3.6%Return on equity3
0.36×Debt to equity3
$39.6MFree cash flow3
What sells
Revenue by product, business segment and region, as the company reports it to the SEC.
Products and services
Product brought in 82% of the revenue MESA LABORATORIES INC /CO/ broke down this way in fiscal 2026.
Products and services by year
| Products and services | 2024 | 2025 | 2026 |
|---|---|---|---|
| Product | $176.8M | $198.4M | $203.4M |
| Service | $39.4M | $42.6M | $45.7M |
Business segments
Sterilization and Disinfection Control brought in 41% of the revenue MESA LABORATORIES INC /CO/ broke down this way in fiscal 2026.
Business segments by year
| Business segments | 2024 | 2025 | 2026 |
|---|---|---|---|
| Sterilization and Disinfection Control | $75.1M | $93.4M | $101.6M |
| Calibration Solutions | $47.8M | $51.7M | $53.6M |
| Biopharmaceutical Development | $40.7M | $48.7M | $48.6M |
| Clinical Genomics | $52.6M | $47.1M | $45.4M |
Regions
United States brought in 47% of the revenue MESA LABORATORIES INC /CO/ broke down this way in fiscal 2026.
Regions by year
| Regions | 2024 | 2025 | 2026 |
|---|---|---|---|
| United States | $106.4M | $116.6M | $116.9M |
| Other | $84.9M | $99.1M | $111.8M |
| [China [Member]] | $24.9M | $25.3M | $20.4M |
Where the money goes
Where each dollar of revenue went, fiscal 2026
- Cost of revenue36¢$90.9M
- Research and development8¢$20.3M
- Other costs51¢$125.9M
- Income tax2¢$5.3M
- Profit3¢$6.7M
Out of $249.1M in revenue.3
Where each dollar of operating cash went, fiscal 2026
- Capital spending8¢$3.2M
- Dividends paid8¢$3.5M
- Kept or used elsewhere84¢$36.1M
Out of $42.8M of cash from operations.3
Financial statements
Every line of the income statement as filed: the last 3 fiscal years, latest first.3
| Period ending | 2026-03-31 | 2025-03-31 | 2024-03-31 |
|---|---|---|---|
| Revenue | $249.1M | $241.0M | $216.2M |
| Cost of revenue | $90.9M | $90.1M | $82.9M |
| Gross profit | $158.3M | $150.9M | $133.2M |
| Selling | $40.8M | $41.7M | $38.6M |
| General and administrative, other than impairment of finite-lived intangible assets and goodwill | $78.7M | $73.3M | $72.9M |
| Research and development | $20.3M | $19.5M | $19.3M |
| Impairment of finite-lived intangible assets | $0 | $0 | $117.6M |
| Impairment of goodwill | $0 | $0 | $156.9M |
| Total operating expense | $139.8M | $134.5M | $405.3M |
| Operating income (loss) | $18.5M | $16.3M | -$272.1M |
| Interest expense and amortization of debt issuance costs | $10.7M | $11.9M | $5.7M |
| Gain on extinguishment of convertible senior notes | $0 | -$2.9M | $0 |
| Other (income) expense, net | -$4.2M | $1.4M | -$2.1M |
| Total nonoperating expense, net | $6.5M | $10.4M | $3.6M |
| Earnings (loss) before income taxes | $12.0M | $6.0M | -$275.6M |
| Income tax expense (benefit) | $5.3M | $7.9M | -$21.4M |
| Net income (loss) | $6.7M | -$2.0M | -$254.2M |
| Basic earnings (loss) per share (in dollars per share) | $1.22 | -$0.36 | -$47.20 |
| Diluted earnings (loss) per share (in dollars per share) | $1.21 | -$0.36 | -$47.20 |
| Basic (in shares) | 5.5M shares | 5.4M shares | 5.4M shares |
| Diluted (in shares) | 5.6M shares | 5.4M shares | 5.4M shares |
No quarter-by-quarter statement was filed.
Every line of the balance sheet as filed: the last 4 fiscal years (annual) or 4 quarters (quarterly), latest first.3
| Period ending | 2026-03-31 | 2025-03-31 | 2024-03-31 | 2023-03-31 |
|---|---|---|---|---|
| Cash and cash equivalents | $26.9M | $27.3M | ||
| Accounts receivable, less allowances for credit losses of $2,569 and $1,186, respectively | $44.1M | $42.0M | ||
| Inventories | $26.4M | $25.4M | ||
| Prepaid expenses and other current assets | $8.9M | $8.0M | ||
| Total current assets | $106.3M | $102.7M | ||
| Property, plant and equipment, net | $30.6M | $32.3M | ||
| Deferred tax asset | $1.5M | $1.4M | ||
| Other Assets, Noncurrent | $19.2M | $18.3M | ||
| Intangible assets | $83.3M | $96.9M | ||
| Goodwill | $186.9M | $181.8M | $180.1M | |
| Total assets | $427.7M | $433.3M | ||
| Accounts payable | $4.9M | $5.7M | ||
| Accrued payroll and benefits | $19.0M | $17.9M | ||
| Unearned revenues | $14.7M | $14.7M | ||
| Other accrued expenses | $17.6M | $24.6M | ||
| Term loan, current portion | $5.6M | $3.8M | ||
| Convertible senior notes, current portion, net of debt issuance costs | $0 | $97.3M | ||
| Total current liabilities | $61.9M | $164.0M | ||
| Deferred tax liability | $20.1M | $20.2M | ||
| Other Liabilities, Noncurrent | $13.7M | $12.5M | ||
| Noncurrent portion | $61.4M | $66.9M | ||
| Revolving line of credit | $84.5M | $10.0M | ||
| Total liabilities | $241.5M | $273.5M | ||
| Common stock, no par value; authorized 25,000,000 shares; issued and outstanding, 5,524,931 and 5,455,421 shares, respectively | $375.3M | $358.5M | ||
| (Accumulated deficit) | -$185.7M | -$188.9M | ||
| Accumulated other comprehensive (loss) | -$3.4M | -$9.8M | ||
| Total stockholders equity | $186.2M | $159.8M | $145.4M | $393.5M |
| Total liabilities and stockholders equity | $427.7M | $433.3M | ||
| Allowance for doubtful accounts receivable | $2.6M | $1.2M | ||
| Common stock, no par value (in dollars per share) | $0 | $0 | ||
| Common stock, authorized (in shares) | 25.0M shares | 25.0M shares | ||
| Common stock, issued (in shares) | 5.5M shares | 5.5M shares | ||
| Common stock, outstanding (in shares) | 5.5M shares | 5.5M shares |
| Period ending | 2026-03-31 | 2025-03-31 | 2024-03-31 | 2023-03-31 |
|---|---|---|---|---|
| Cash and cash equivalents | $26.9M | $27.3M | ||
| Accounts receivable, less allowances for credit losses of $2,569 and $1,186, respectively | $44.1M | $42.0M | ||
| Inventories | $26.4M | $25.4M | ||
| Prepaid expenses and other current assets | $8.9M | $8.0M | ||
| Total current assets | $106.3M | $102.7M | ||
| Property, plant and equipment, net | $30.6M | $32.3M | ||
| Deferred tax asset | $1.5M | $1.4M | ||
| Other Assets, Noncurrent | $19.2M | $18.3M | ||
| Intangible assets | $83.3M | $96.9M | ||
| Goodwill | $186.9M | $181.8M | $180.1M | |
| Total assets | $427.7M | $433.3M | ||
| Accounts payable | $4.9M | $5.7M | ||
| Accrued payroll and benefits | $19.0M | $17.9M | ||
| Unearned revenues | $14.7M | $14.7M | ||
| Other accrued expenses | $17.6M | $24.6M | ||
| Term loan, current portion | $5.6M | $3.8M | ||
| Convertible senior notes, current portion, net of debt issuance costs | $0 | $97.3M | ||
| Total current liabilities | $61.9M | $164.0M | ||
| Deferred tax liability | $20.1M | $20.2M | ||
| Other Liabilities, Noncurrent | $13.7M | $12.5M | ||
| Noncurrent portion | $61.4M | $66.9M | ||
| Revolving line of credit | $84.5M | $10.0M | ||
| Total liabilities | $241.5M | $273.5M | ||
| Common stock, no par value; authorized 25,000,000 shares; issued and outstanding, 5,524,931 and 5,455,421 shares, respectively | $375.3M | $358.5M | ||
| (Accumulated deficit) | -$185.7M | -$188.9M | ||
| Accumulated other comprehensive (loss) | -$3.4M | -$9.8M | ||
| Total stockholders equity | $186.2M | $159.8M | $145.4M | $393.5M |
| Total liabilities and stockholders equity | $427.7M | $433.3M | ||
| Allowance for doubtful accounts receivable | $2.6M | $1.2M | ||
| Common stock, no par value (in dollars per share) | $0 | $0 | ||
| Common stock, authorized (in shares) | 25.0M shares | 25.0M shares | ||
| Common stock, issued (in shares) | 5.5M shares | 5.5M shares | ||
| Common stock, outstanding (in shares) | 5.5M shares | 5.5M shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow as filed: the last 3 fiscal years, latest first.3
| Period ending | 2026-03-31 | 2025-03-31 | 2024-03-31 |
|---|---|---|---|
| Net income (loss) | $6.7M | -$2.0M | -$254.2M |
| Depreciation of property, plant and equipment | $2.1M | $2.2M | $4.2M |
| Amortization of acquisition-related intangibles | $2.8M | $19.1M | $6.1M |
| Stock-based compensation expense | $17.9M | $13.1M | $11.9M |
| Non-cash interest expense and debt issuance cost amortization | $682.0K | $990.0K | $926.0K |
| Gain on extinguishment of convertible senior notes | $0 | -$2.9M | $0 |
| Amortization of step-up in inventory basis | $0 | $1.2M | $1.2M |
| Deferred taxes | -$1.3M | -$72.0K | -$28.4M |
| Impairment loss on goodwill and finite-lived intangible assets | $0 | $0 | $274.5M |
| Other | $577.0K | $4.9M | $629.0K |
| Accounts receivable | -$3.2M | -$2.9M | $4.9M |
| Inventories | -$4.4M | $1.2M | $2.6M |
| Prepaid expenses and other assets | $608.0K | $498.0K | $211.0K |
| Accounts payable | -$1.2M | -$388.0K | -$97.0K |
| Accrued liabilities and taxes payable | $3.5M | $9.5M | -$1.2M |
| Unearned revenues | -$255.0K | -$938.0K | -$408.0K |
| Net cash provided by operating activities | $42.8M | $46.8M | $44.1M |
| Purchases of property, plant and equipment | -$3.2M | -$4.2M | -$2.6M |
| Acquisition of customer lists | $0 | -$250.0K | $0 |
| Acquisition of businesses, net of cash acquired and holdback liabilities | $0 | $0 | -$78.7M |
| Net cash (used in) investing activities | -$3.2M | -$4.5M | -$81.3M |
| Proceeds from debt borrowings | $107.5M | $73.5M | $71.0M |
| Repurchase of convertible note debt | -$97.5M | -$71.6M | $0 |
| Other debt principal repayments | -$36.7M | -$44.3M | -$33.5M |
| GKE acquisition holdback payment | -$9.6M | $0 | $0 |
| Dividends paid | -$3.5M | -$3.5M | -$3.4M |
| Payment of tax withholding obligation on vesting of restricted stock | -$1.1M | -$887.0K | -$728.0K |
| Proceeds from the exercise of stock options | $0 | $2.6M | $358.0K |
| Other financing, net | -$966.0K | -$452.0K | -$847.0K |
| Net cash (used in) provided by financing activities | -$41.9M | -$44.5M | $32.8M |
| Net (decrease) in cash and cash equivalents | -$393.0K | -$893.0K | -$4.7M |
| Effect of exchange rate changes on cash and cash equivalents | $1.9M | $1.3M | -$359.0K |
| Income taxes | $1.9M | $5.7M | $4.6M |
| Interest | $10.0M | $11.1M | $4.6M |
No quarter-by-quarter statement was filed.
Corporate structure
MESA LABORATORIES INC /CO/ sits at the top of its group. 14 entities, 8 countries on record. Switch between the flow chart and the network, and select any entity to see its details.
Major holders of MESA LABORATORIES INC /CO/
- WASATCH ADVISORS LP Filed SCHEDULE 13G on MESA LABORATORIES INC /CO/, latest Oct 9, 2026
- Long Path Smaller Companies Fund, LP Filed SCHEDULE 13G/A on MESA LABORATORIES INC /CO/, latest Jul 7, 2026 (3 filings since Mar 13, 2026)
- VANGUARD GROUP INC Filed SCHEDULE 13G/A on MESA LABORATORIES INC /CO/, latest Mar 27, 2026 (5 filings since Feb 10, 2022)
- BlackRock Filed SCHEDULE 13G/A on MESA LABORATORIES INC /CO/, latest Oct 2, 2025 (7 filings since Jan 25, 2022)
- ROYCE & ASSOCIATES LP Filed SCHEDULE 13G/A on MESA LABORATORIES INC /CO/, latest Apr 30, 2025 (6 filings since Jan 21, 2022)
- Conestoga Capital Advisors, LLC Filed SCHEDULE 13G/A on MESA LABORATORIES INC /CO/, latest Jan 10, 2025 (5 filings since Jan 10, 2022)
- Invesco Filed SC 13G/A on MESA LABORATORIES INC /CO/, latest Feb 2, 2023 (2 filings since Feb 10, 2022)
- PRICE T ROWE ASSOCIATES INC /MD/ Filed SC 13G/A on MESA LABORATORIES INC /CO/, latest Feb 14, 2022
- MESA LABORATORIES INC /CO/ Lakewood, Colorado, United States
- Agena Bioscience China Subsidiary · China
- Agena Bioscience GmbH Subsidiary · Germany
- Agena Bioscience HK Subsidiary · China
- Beijing GKE Science & Technology Co. Ltd. Subsidiary · China
- Gyros DE GmbH Subsidiary · Germany
- Gyros Japan KK Subsidiary · Japan
- Gyros Protein Technology AB Subsidiary · Sweden
- Gyros U.K. Ltd. Subsidiary · United Kingdom
- IBP Medical GmbH Subsidiary · Germany
- Mesa Canada, Inc. Subsidiary · Canada
- MESA FRANCE Subsidiary · Chassieu, France
- Mesa Germany GmbH Subsidiary · Germany
- SAL GmbH Subsidiary · Germany
Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); subsidiaries listed in Exhibit 21 of annual reports filed with the SEC; major holders from Schedules 13D and 13G. Each entity in the chart links to its source.
What it owns
What MESA LABORATORIES INC /CO/ reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.
Property and equipment
| Item | Latest | A year before | Change |
|---|---|---|---|
| Land | $889.0K3 Mar 31, 2026 | $889.0K3 Mar 31, 2025 | 0% |
| Buildings and improvements | $23.4M3 Mar 31, 2026 | $23.3M3 Mar 31, 2025 | +0.4% |
| Machinery and equipment | $3.7M3 Mar 31, 2026 | $3.1M3 Mar 31, 2025 | +18.3% |
| Construction in progress | $1.5M3 Mar 31, 2026 | $1.6M3 Mar 31, 2025 | −8.9% |
| Property and equipment, before depreciation | $60.7M3 Mar 31, 2026 | $58.8M3 Mar 31, 2025 | +3.4% |
| Accumulated depreciation | $30.1M3 Mar 31, 2026 | $26.4M3 Mar 31, 2025 | +14.0% |
| Property and equipment, net | $30.6M3 Mar 31, 2026 | $32.3M3 Mar 31, 2025 | −5.3% |
| Operating-lease assets (leased space) | $17.5M3 Mar 31, 2026 | $16.4M3 Mar 31, 2025 | +6.8% |
Investments
Intangibles and goodwill
| Item | Latest | A year before | Change |
|---|---|---|---|
| Goodwill | $186.9M3 Mar 31, 2026 | $181.8M3 Mar 31, 2025 | +2.8% |
| Finite-lived intangibles, gross | $248.5M3 Mar 31, 2026 | $251.3M3 Mar 31, 2025 | −1.1% |
| Accumulated amortization | $165.2M3 Mar 31, 2026 | $154.4M3 Mar 31, 2025 | +7.0% |
| Finite-lived intangibles, net | $83.3M3 Mar 31, 2026 | $96.9M3 Mar 31, 2025 | −14.0% |
Inventory
| Item | Latest | A year before | Change |
|---|---|---|---|
| Inventory, total | $26.4M3 Mar 31, 2026 | $25.4M3 Mar 31, 2025 | +4.0% |
| Raw materials | $14.9M3 Mar 31, 2026 | $14.8M3 Mar 31, 2025 | +0.7% |
| Work in process | $925.0K3 Mar 31, 2026 | $560.0K3 Mar 31, 2025 | +65.2% |
| Finished goods | $10.6M3 Mar 31, 2026 | $10.0M3 Mar 31, 2025 | +5.4% |
Properties, in its own words
As of March 31, 2026, we owned two facilities, both of which are material to our business: a facility in Lakewood, Colorado used by our Calibration Solutions division, and a facility in Bozeman, Montana used by our Sterilization and Disinfection Control division. We also lease multiple properties used by our Sterilization and Disinfection Control, Biopharmaceutical Development, Calibration Solutions, and Clinical Genomics divisions. Significant leased locations include our Biopharmaceutical Development facility in Sweden, a facility used by our Clinical Genomics division in the United States, and facilities in Germany used primarily by our Sterilization and Disinfection Control division. Our owned and leased facilities are used for manufacturing and distribution, research and development, sales and marketing, and administration activities. We believe our properties are suitable and adequate to carry out our business.
Item 2 of the 10-K filed Jun 3, 2026.6
Leadership
Who has led MESA LABORATORIES INC /CO/, and when. Pick a name to see everywhere that person has worked.
Chief financial officer
Chief operating officer
2010201520202025
- Chief executive officerSiddhartha Kadia Apr 24, 2026 to now16
- Chief executive officerGary M. Owens Sep 1, 2017 to Apr 24, 202617
- Chief executive officerLuke R. Schmieder Feb 7, 2006 to Feb 12, 200918
- ChairLuke R. Schmieder Nov 17, 2006 to Feb 12, 200919
- PresidentSiddhartha Kadia Apr 24, 2026 to now16
- PresidentGary M. Owens Sep 1, 2017 to Apr 24, 202617
- PresidentLuke R. Schmieder Feb 7, 2006 to Apr 28, 200618
- Chief financial officerJohn Sakys V. Dec 3, 2012 to now20
- Chief operating officerGary M. Owens Mar 22, 2017 to Mar 22, 201721
Board members and other officers (19)
- Chief Accounting OfficerLyndsey Elizabeth Crennen Jun 16, 2026 to now22
- SVP of Continuous ImprovementBrian David Archbold Jun 13, 2019 to now23
- SVP Commercial OperationsGregory Dinoia Oct 24, 2018 to Jun 22, 202224
- Former DirectorLuke R. Schmieder Apr 28, 2015 to Apr 28, 201525
- Executive Vice PresidentMichael Tranmer Sep 28, 2011 to Apr 2, 201226
- VP Sales & MarketingGlenn E. Adriance Apr 4, 2008 to Mar 26, 201827
- Board memberMark Christopher Capone Feb 16, 2024 to now28
- Board memberR. Tony Tripeny Jul 11, 2022 to now29
- Board memberShiraz Shabanali Ladiwala Nov 8, 2021 to now30
- Board memberShannon Hall Jun 2, 2020 to now31
- Board memberDavid Brian Perez Jan 25, 2019 to Jun 17, 202032
- Board memberJennifer Sadie Alltoft Apr 8, 2019 to now33
- Board memberGary M. Owens Sep 1, 2017 to Sep 1, 202117
- Board memberJohn Bradley Schmieder Apr 9, 2015 to Sep 19, 202334
- Board memberDavid M. Kelly Oct 12, 2010 to Nov 9, 202135
- Board memberEvan Guillemin Feb 25, 2009 to Sep 2, 202236
- Board memberPaul D. Duke Jan 13, 2006 to May 24, 201037
- Board memberLuke R. Schmieder Feb 7, 2006 to Nov 19, 201418
- Board memberH. Stuart Campbell Mar 21, 2006 to Nov 28, 201838
Subsidiaries and ownership
Subsidiaries (Exhibit 21)
- Agena Bioscience China China5
- Agena Bioscience GmbH Germany5
- Agena Bioscience HK China5
- Beijing GKE Science & Technology Co. Ltd. China5
- Gyros DE GmbH Germany5
- Gyros Japan KK Japan5
- Gyros Protein Technology AB Sweden5
- Gyros U.K. Ltd. United Kingdom5
- IBP Medical GmbH Germany5
- Mesa Canada, Inc. Canada5
- Mesa France SAS France5
- Mesa Germany GmbH Germany5
- SAL GmbH Germany5
The subsidiaries the company lists in Exhibit 21 of its annual report, as filed.
Former names
- MESA LABORATORIES INC /CODec 11, 1995 to Aug 28, 20204
Timeline
- Oct 13, 20268-K Exit or restructuring costs; Regulation FD disclosure39
- Sep 8, 20268-K Shareholder vote40
- Aug 10, 20268-K Results of operations41
- Jul 30, 20268-K Code of ethics changed42
- Jun 15, 20268-K Executive or director change43
- May 27, 20268-K Results of operations44
- Apr 24, 2026New chief executive Siddhartha Kadia becomes CEO16
- Mar 23, 20268-K Executive or director change45
- Mar 9, 20268-K Executive or director change; Regulation FD disclosure46
- Feb 3, 20268-K Results of operations47
- Nov 6, 20258-K Results of operations48
- Aug 25, 20258-K Shareholder vote49
- Aug 18, 20258-K New debt or obligation50
- Sep 1, 2017New chief executive Gary M. Owens becomes CEO17
- Feb 7, 2006New chief executive Luke R. Schmieder becomes CEO18
- Mar 26, 1982Founded MESA LABORATORIES INC /CO/ is founded2
Calendar
Coming up
- Nov 5, 2026Reports results for the quarter ending Sep/202651
- Nov 30, 2026Dividend Ex-dividend; $0.16 a share; paid 2026-12-15.52
When it reported results
- Aug 10, 2026Reported quarterly or annual results41
- May 27, 2026Reported quarterly or annual results44
- Feb 3, 2026Reported quarterly or annual results47
- Nov 6, 2025Reported quarterly or annual results48
- Aug 5, 2025Reported quarterly or annual results53
- May 28, 2025Reported quarterly or annual results54
- Feb 4, 2025Reported quarterly or annual results55
- Nov 7, 2024Reported quarterly or annual results56
Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar
Filings
326 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 53 major events, 182 insider forms, 30 large holders, 41 other. The latest 20:
- Oct 13, 20268-K EDGAR
- Oct 9, 2026SCHEDULE 13G EDGAR
- Sep 11, 20264 PRIMARY DOCUMENT EDGAR
- Sep 11, 20264 PRIMARY DOCUMENT EDGAR
- Sep 11, 20264 PRIMARY DOCUMENT EDGAR
- Sep 11, 20264 PRIMARY DOCUMENT EDGAR
- Sep 11, 20264 PRIMARY DOCUMENT EDGAR
- Sep 11, 20264 PRIMARY DOCUMENT EDGAR
- Sep 8, 20268-K EDGAR
- Aug 27, 2026144 EDGAR
- Aug 21, 2026144 EDGAR
- Aug 17, 20264 PRIMARY DOCUMENT EDGAR
- Aug 17, 20264 PRIMARY DOCUMENT EDGAR
- Aug 17, 20264 PRIMARY DOCUMENT EDGAR
- Aug 17, 20264 PRIMARY DOCUMENT EDGAR
- Aug 17, 20264 PRIMARY DOCUMENT EDGAR
- Aug 17, 20264 PRIMARY DOCUMENT EDGAR
- Aug 17, 20264 PRIMARY DOCUMENT EDGAR
- Aug 17, 20264 PRIMARY DOCUMENT EDGAR
- Aug 17, 20264 PRIMARY DOCUMENT EDGAR
The 326 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last five years, summarized. The full record is on SEC EDGAR.
Insider trades
60 open-market trades by officers, directors and large owners since October 2021: 6 buys and 54 sales. Grants, option exercises and gifts are left out.
| Date | Who | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Aug 13, 2026 | Sullivan John JamesDirector | Sale | 7,093 | $112.80 | $800.1K | Form 4 |
| Aug 13, 2026 | Kadia SiddharthaPresident and CEO | Buy | 7,093 | $112.80 | $800.1K | Form 4 |
| Aug 13, 2026 | Tripeny R TonyDirector | Buy | 900 | $113.69 | $102.3K | Form 4 |
| Jun 22, 2026 | Crennen Lyndsey ElizabethCAO | Sale | 442 | $89.50 | $39.6K | Form 4 |
| Jun 22, 2026 | Archbold Brian DavidSVP Operations | Sale | 2,516 | $89.50 | $225.2K | Form 4 |
| Jun 22, 2026 | Sakys JohnCFO | Sale | 2,827 | $89.50 | $253.0K | Form 4 |
| Jun 16, 2026 | Archbold Brian DavidSVP Operations | Sale | 1,151 | $101.27 | $116.6K | Form 4 |
| Jun 16, 2026 | Crennen Lyndsey ElizabethCAO | Sale | 118 | $101.27 | $11.9K | Form 4 |
| Jun 16, 2026 | Sakys JohnCFO | Sale | 1,223 | $101.27 | $123.9K | Form 4 |
| Mar 10, 2026 | Ladiwala Shiraz ShabanaliDirector | Buy | 3,500 | $72.23 | $252.8K | Form 4 |
| Mar 10, 2026 | Capone Mark ChristopherDirector | Buy | 1,301 | $76.35 | $99.3K | Form 4 |
| Mar 10, 2026 | Tripeny R TonyDirector | Buy | 1,315 | $76.00 | $99.9K | Form 4 |
| Jun 16, 2025 | Owens Gary MPresident and CEO | Sale | 1,939 | $97.12 | $188.3K | Form 4 |
| Jun 16, 2025 | Archbold Brian DavidSVP Operations | Sale | 472 | $97.12 | $45.8K | Form 4 |
| Jun 16, 2025 | Sakys JohnCFO | Sale | 642 | $97.12 | $62.4K | Form 4 |
| Mar 19, 2025 | Owens Gary MPresident and CEO | Sale | 21,000 | $123.91 | $2.6M | Form 4 |
| Oct 29, 2024 | Owens Gary MPresident and CEO | Sale | 2,551 | $111.98 | $285.7K | Form 4 |
| Oct 28, 2024 | Owens Gary MPresident and CEO | Sale | 2,518 | $113.62 | $286.1K | Form 4 |
| Sep 13, 2024 | Archbold Brian DavidSVP Operations | Sale | 1,499 | $125.00 | $187.4K | Form 4 |
| Dec 15, 2023 | Archbold Brian DavidSVP Operations | Sale | 1,500 | $112.36 | $168.5K | Form 4 |
All 60 trades can be filtered by person here when JavaScript is on.
From Forms 4 filed with the SEC.
Major holders
Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.
- WASATCH ADVISORS LPSCHEDULE 13G, 1 filing Oct 9, 202657
- Long Path Smaller Companies Fund, LPSCHEDULE 13G/A, 3 filings Mar 13, 2026 to Jul 7, 202658
- VANGUARD GROUP INCSCHEDULE 13G/A, 5 filings Feb 10, 2022 to Mar 27, 202659
- BlackRockSCHEDULE 13G/A, 7 filings Jan 25, 2022 to Oct 2, 202560
- ROYCE & ASSOCIATES LPSCHEDULE 13G/A, 6 filings Jan 21, 2022 to Apr 30, 202561
- Conestoga Capital Advisors, LLCSCHEDULE 13G/A, 5 filings Jan 10, 2022 to Jan 10, 202562
- InvescoSC 13G/A, 2 filings Feb 10, 2022 to Feb 2, 202363
- PRICE T ROWE ASSOCIATES INC /MD/SC 13G/A, 1 filing Feb 14, 202264
Executive pay
What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.
| Year | Executive | Age | Salary | Total pay |
|---|---|---|---|---|
| 2026 | Gary Owens | $808.8K | $6.6M65 | |
| 2026 | John Sakys | $498.4K | $2.5M65 | |
| 2026 | Brian Archbold | $437.0K | $2.2M65 | |
| 2025 | Former CEO and President | $778.0K | $6.6M65 | |
| 2025 | VP and Chief Financial Officer | $474.3K | $2.4M65 | |
| 2025 | SVP of Operations and Continuous Improvement | $417.2K | $2.1M65 | |
| 2024 | Former CEO and President | $754.0K | $5.4M65 | |
| 2024 | VP and Chief Financial Officer | $452.0K | $1.9M65 | |
| 2024 | SVP of Operations and Continuous Improvement | $404.0K | $1.6M65 |
Held by these funds
The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.
13F reports cover disclosed long positions in U.S. stocks only.
SEC filer profile
How MESA LABORATORIES INC /CO/ is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.
- Name on EDGARMESA LABORATORIES INC /CO/1
- CIK0000724004
- Employer ID (EIN)84-08722916
- Filer statusAccelerated filer not an emerging growth company; not a smaller reporting company; not a shell company6
- Incorporated inColorado6
- Fiscal year endsMarch 311
- Industry code (SIC)3823 Industrial Instruments For Measurement, Display, and Control1
- SEC reviewing officeOffice of Industrial Applications and Services, Division of Corporation Finance1
- Business address12100 W 6Th Ave, Lakewood, CO 802281
- Phone30398780001
- Shares outstanding5,595,869 as of Aug 3, 202614
- Public float$358.0M as of Sep 30, 20256
- AuditorBaker Tilly LLP, Los Angeles, California PCAOB ID 23; it also attests to the company’s internal control over financial reporting6
- On EDGAR sinceDec 11, 19951
- Filings1,322 in all: 4 (675), 8-K (226), 10-Q (58), SC 13G/A (53), 10QSB (35), DEF 14A (31), 144 (21), 3 (20)1
All 42 form types
4/A (20), UPLOAD (20), 10-K (19), CORRESP (18), 10KSB (12), 8-K/A (10), S-8 (9), SCHEDULE 13G/A (9), SD (9), SC 13G (8), 10-Q/A (7), 424B5 (7), 10QSB/A (6), 10-K/A (4), 3/A (4), DEFA14A (4), 424B3 (3), 5 (3), EFFECT (3), S-3 (3), SC 13D/A (3), 10KSB/A (2), DEFR14A (2), NT 10-K (2), PRE 14A (2), RW (2), S-3/A (2), S-3ASR (2), SC 13D (2), SCHEDULE 13G (2), FWP (1), NT 10-Q (1), POS AM (1), PX14A6G (1)
- Latest filingsAnnual report (10-K) Jun 3, 2026
Quarterly report (10-Q) Aug 10, 2026
Proxy statement (DEF 14A) Jul 22, 2026
Latest 8-K (8-K) Oct 13, 2026
Securities registered for trading
| Class | Symbol | Exchange |
|---|---|---|
| Common stock, no par value | MLAB | Nasdaq |
From the cover page of the 10-K filed Jun 3, 2026 (Section 12(b) of the Exchange Act).6
Risk factors and legal proceedings
The risks MESA LABORATORIES INC /CO/ names in Item 1A of its 10-K filed Jun 3, 2026: 46 risks under these headings, as written.6
- Business and Strategic Risks
- Conditions in the global economy, the markets we serve, and financial markets may adversely affect our business, financial statements, and access to capital markets.
- Our international operations subject us to a wide range of risks.
- Our growth could suffer if the markets into which we sell our products and services decline, do not grow as anticipated or experience volatility.
- We face competition and if we are unable to compete effectively, we may experience reduced demand for our products and services and a loss of market share, which could result in decreased revenues. Even if we compete effectively, competitive pressures may require us to reduce prices or offer other concessions, which could decrease our profit margins.
- Industry consolidation and shifts in customer behavior could adversely affect our results of operations.
- Our growth depends in part on the timely development, commercialization, and customer acceptance of new and enhanced products and services based on technological innovation.
- Our success depends on our ability to recruit, retain and motivate skilled employees, and changes to our management team may not provide the benefits we expect.
- Adverse changes in our relationships with, or the financial condition, performance, or purchasing patterns of, distributors and other channel partners could adversely affect our business, results of operations, and financial condition.
- Uncertainties related to the use of artificial intelligence (“AI”) in our business may result in harm to our business and reputation.
- Operational Risks
- Geopolitical pressures in the markets in which we operate may adversely affect our financial results.
The other 36 risks
- A significant disruption in, or breach in security of, our information technology systems or data could adversely affect our business, reputation and financial statements.
- Disruptions in our supply chains, increases in costs, or manufacturing inefficiencies could adversely affect our financial results. In addition, our reliance upon sole or limited sources of supply for certain materials, components and services could cause production interruptions, delays and inefficiencies.
- We may be unable to efficiently manage our growth as a larger and more geographically diverse organization.
- Cost reduction or efficiency initiatives may not achieve anticipated benefits and may involve higher-than-expected transition or implementation costs.
- The life sciences, pharmaceutical, healthcare and related industries we serve have undergone, and continue to undergo, significant changes in an effort to reduce costs, which could adversely affect our financial results.
- The manufacture of many of our products is a highly exacting and complex process, and if we directly or indirectly encounter problems manufacturing products, our reputation, business and financial results could suffer.
- Changes to dialysis methods and equipment capabilities may decrease demand for our renal care products and negatively impact our business, results of operations, and financial condition.
- Violation of data privacy laws could adversely affect our business, reputation and financial statements.
- If we suffer loss to our facilities, supply chains, distribution systems or information technology systems due to a catastrophic event, our operations could be seriously harmed.
- Climate change, as well as legal or regulatory measures and stakeholder expectations related to climate change and sustainability, may negatively affect our business and financial results, and any actions we take or fail to take in response to such matters could damage our reputation.
- Acquisition Risks
- Any inability to consummate acquisitions at our historical rate and at appropriate prices could negatively impact our growth rate and stock price.
- The indemnification provisions of acquisition agreements by which we have acquired companies may not fully protect us, which could result in unexpected liabilities.
- Future strategic transactions or acquisitions may require us to seek additional financing, which we may not be able to secure on favorable terms, or at all.
- Legal, Regulatory, Compliance, and Reputational Risks
- Changes in trade policies, tariffs, or industrial policies may increase our costs, disrupt our supply chain, or adversely affect demand for our products.
- We are subject to extensive and evolving regulatory requirements that affect the approval, manufacture, marketing and commercialization of our products.
- Evolving cybersecurity regulations, including the European Union’s Cyber Resilience Act, may increase our compliance costs and require changes to our products and processes.
- Off-label marketing of our products could result in substantial penalties.
- Certain modifications to our products may require new 510(k) clearances or other marketing authorizations and may require us to recall or cease marketing our products.
- Changes in governmental regulations or regulatory enforcement may reduce demand for our products or services or increase our expenses.
- Potential product liability suits against us, product defects, unanticipated use or inadequate disclosure related to our products or services could adversely affect our business, reputation, results of operations, and financial condition.
- We are subject to lawsuits, investigations and regulatory proceedings that could result in significant costs, penalties, or liabilities.
- Our reputation, ability to do business and prepare financial statements may be impaired by improper conduct by any of our employees, agents or business partners.
- If we do not adequately protect our intellectual property, if third parties infringe our intellectual property rights, or if we or our customers are alleged to infringe upon others’ intellectual property rights, we may suffer competitive injury or expend significant resources enforcing or defending our rights.
- We are subject to export and import control laws and regulations that could impair our ability to compete in international markets or subject us to liability if we violate such laws and regulations.
- We are subject to laws and regulations governing government contracts.
- Financial and Tax Risks
- Foreign currency exchange rates may adversely affect our financial statements.
- The loss of key customers, or reductions in their demand for our products and services, could have a significant adverse effect on our revenues, results of operations, and financial position.
- If we fail to maintain an effective system of internal controls, we may not be able to accurately report financial results or prevent fraud. If we identify a material weakness in our internal control over financial reporting, our ability to meet our reporting obligations, investor confidence in our financial reporting, our operating results, and the trading price of our stock could be negatively affected.
- We may be required to recognize impairment losses for our goodwill and other intangible assets.
- Changes in accounting standards and subjective assumptions, estimates and judgments by management related to complex accounting matters could affect our reported financial results.
- Changes in our tax rates or exposure to additional income tax liabilities or assessments could affect our profitability. In addition, audits by tax authorities could result in additional tax payments for prior periods.
- Changes in tax law relating to multinational corporations could adversely affect our tax position.
- Servicing our debt will require a significant amount of cash, and deterioration in our financial performance or in global credit market conditions could adversely affect our ability to obtain financing or to fund our existing debt obligations.
- Additional stock issuances could result in significant dilution to our stockholders.
- The market price of our common stock may be volatile, which may subject us to securities class action litigation or cause shareholders to lose part or all of their investment.
- Failure to maintain appropriate corporate responsibility practices and disclosures could result in reputational harm, a loss of customer and investor confidence, and adverse business and financial results.
Legal proceedings
For information regarding legal proceedings, refer to Note 13. “Commitments and Contingencies” in our Consolidated Financial Statements included in Item 8. Financial Statements and Supplementary Data.
The opening of Item 3, Legal Proceedings.6
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19SEC EDGARLuke R. Schmieder, Chair
- 20
- 21
- 22
- 23
- 24
- 25SEC EDGARLuke R. Schmieder, Former Director
- 26
- 27
- 28
- 29SEC EDGARR. Tony Tripeny, Board member
- 30
- 31SEC EDGARShannon Hall, Board member
- 32SEC EDGARDavid Brian Perez, Board member
- 33SEC EDGARJennifer Sadie Alltoft, Board member
- 34SEC EDGARJohn Bradley Schmieder, Board member
- 35SEC EDGARDavid M. Kelly, Board member
- 36SEC EDGAREvan Guillemin, Board member
- 37SEC EDGARPaul D. Duke, Board member
- 38SEC EDGARH. Stuart Campbell, Board member
- 39
- 40SEC EDGARShareholder vote
- 41SEC EDGARResults of operations
- 42SEC EDGARCode of ethics changed
- 43SEC EDGARExecutive or director change
- 44SEC EDGARResults of operations
- 45SEC EDGARExecutive or director change
- 46
- 47SEC EDGARResults of operations
- 48SEC EDGARResults of operations
- 49SEC EDGARShareholder vote
- 50SEC EDGARNew debt or obligation
- 51NasdaqNasdaq calendar
- 52NasdaqNasdaq calendar
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60
- 61
- 62
- 63
- 64
- 65